Sinocare announced its annual performance, with shareholders' net profit of approximately 180 million yuan, turning a loss into a profit compared to the previous year.

Sina Finance reported on March 31st that Sihuan Pharmaceutical released its annual performance report for the year ending December 31, 2025. The total revenue is approximately 2.618 billion yuan, an increase of about 37.7% year-on-year. The gross profit is about 1.802 billion yuan, an increase of about 45.1% year-on-year. The overall research and development expenses are about 291 million yuan, a decrease of 38.5% year-on-year. The company's attributable net profit is about 180 million yuan, turning a loss to a profit year-on-year; and the basic earnings per share is 1.97 cents. It is proposed to distribute a final dividend of 0.96 cents per share.